Overview
Balance Sheet
Cash Flow
Growth Analysis
2023
2022
2021
2020
2019
Profitability Metrics
Gross Margin
100.00%
Operating Margin
90.18%
Net Margin
106.22%
Efficiency Metrics
Revenue per Expense Ratio
10.18
R&D as % of Revenue
0.00%
Earnings Quality
EBITDA Margin
0.00%
Income Tax Rate
0.00%
EPS
1.0200000000
Balance Sheet Analysis
Current Ratio
0.09
Cash Ratio
0.01
Working Capital
$-307.05M
Debt to Equity
0.49
Debt to Assets
31.12%
Equity Ratio
63.23%
Cash Flow Analysis
Operating Cash Flow Ratio
55.79%
Free Cash Flow Ratio
55.79%
CapEx to Revenue
0.00%
Dividends Paid
$48.35M
Stock Buybacks
No buybacks
Total Shareholder Returns
$48.35M
Cash Position Change
180.78%
Key Takeaways (2023 FY)
Maintained positive net income growth despite revenue changes
Detailed Growth Metrics
Core Performance
Revenue
125.68%
Net Income
127.20%
EPS
127.13%
Operating Income
123.09%
Operational Efficiency
R&D Expenses
-100.00%
SG&A Expenses
960.08%
Operating Cash Flow
70.31%
Free Cash Flow
70.31%
Balance Sheet Health
Assets
-9.67%
Debt
-24.54%
Book Value per Share
1.18%
Inventory
-100.00%
Shareholder Returns
Dividends per Share
-14.35%
Shares Outstanding
0.00%
Long Term Trends
3Y Revenue/Share
-50.93%
5Y Revenue/Share
-61.36%
3Y Dividend/Share
9.41%
5Y Dividend/Share
16.27%